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TreatmentAbstract Effective pharmacological treatments for drug abuse and addiction have not yet been
identiﬁed. Evidences show that vitamin D may be involved in neurodevelopment and may have a
neuroprotective effect on dopaminergic pathways in the adult brain. The fact that vitamin D
increases the levels of tyrosine hydroxylase expression implies that vitamin D could modulate dopa-
minergic processes. Drugs of abuse act through different mechanisms of action and on different
locations in the brain reward system; however, all of them share a ﬁnal action in which they increase
dopamine levels in the reward pathway. Vitamin D-treated animals showed signiﬁcant attenuated
methamphetamine-induced reductions in dopamine and metabolites when compared to control,
indicating that vitamin D provides protection for the dopaminergic system against the depleting
effects of methamphetamine. In this article, it is speculated that vitamin D would be an effective
treatment approach for drug abuse and addiction, if we consider that vitamin D would provide pro-
tection for the dopaminergic system against dopamine-depleting effects of drugs, as it did for meth-
amphetamine. This hypothesis can provide a new direction towards a new treatment approach for
drug abuse and addiction, as we have no pharmacological treatments at our disposal at the present
moment, although several issues need further investigation.
ª 2013 Tehran University of Medical Sciences. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.Introduction
For some but not all drug users, the recreational use of drugs
turns into addiction, but the reason is still unknown. It is esti-
mated that 230 million people have used illicit drugs at least5, Pre´dio BQ, 5 andar, CEP 01246
.
niversity of Medical Sciences. Pub
h/
/j.jmhi.2013.02.001once during the year 2010 and about 27 million people have
had problems due to drug abuse in the same period. Drug
abuse is a serious public health problem, leading to increased
rates of drug-related deaths and human immunodeﬁciency
virus (HIV), hepatitis C and hepatitis B infection [1]. Effective-900, Sa˜o Paulo, SP, Brazil. Tel.: +55 11 3068 2930; fax: +55 11 3068
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not yet been identiﬁed [2].
Many studies over the last decade have shown evidences
that vitamin D plays an important role in brain development
and function. Although vitamin D has been studied for over
50 years, the link between vitamin D and neuropsychiatric dis-
orders has been proposed for only two decades [3].
Vitamin D and the brain
Vitamin D is classiﬁed as a neurosteroid because of its action
in the brain and like other neurosteroids vitamin D crosses the
blood–brain barrier [4,5]. The vitamin D receptor (VDR) and
the enzymes required for the synthesis of 1,25-dihydroxyvita-
min D3 (1,25(OH)2D3), the active form of vitamin D, are pres-
ent in the brain of several species [4], especially in the
developing rat and mouse brain, indicating that vitamin D
may be involved in neurodevelopment [5]. VDR was found
in the ‘nucleus accumbens’, thalamus, temporal, orbital and
cingulate cortices, amygdala, pyramidal neurons of the hippo-
campus and the olfactory system of neonatal and adult rats [3].
The sites of expression of the VDR change during develop-
ment, leading to the hypothesis that vitamin D may play a role
in brain development [6].
Vitamin D and the dopaminergic system
Evidences show that vitamin D may have a neuroprotective
effect on dopaminergic pathways in the adult brain. When
6-hydroxydopamine (6-OHDA), which is a selective dopami-
nergic toxin, is administered in animals pretreated with
1,25(OH)2D3 for 1 week, the dopaminergic function stays pre-
served [3]. Rats postnatally treated with a single dose of vita-
min D showed increased dopamine (DA) in the brainstem
and alterations in the caudate putamen and hypothalamus
[7]. In vitro, 1,25(OH)2D3 increases the expression of tyrosine
hydroxylase in adrenal medullary cells [4]. The evidence that
vitamin D increases the levels of tyrosine hydroxylase expres-
sion implies that vitamin D could modulate dopaminergic
processes [8–10].
Developmental vitamin D deﬁciency
Developmental vitamin D (DVD)-deﬁcient rats share many
structural and behavioural similarities with patients who devel-
op schizophrenia [11]. Studies investigating the developmental
neurobiological measures of DVD-deﬁcient embryonic and
neonatal rats showed increased volume of lateral ventricles
and decreased cortex thickness (abnormalities usually found
in schizophrenia, which are highly predictive of psychotic risk),
decreased nerve growth factor (NGF) and glial cell line-
derived neurotrophic factor (GDNF), altered DA metabolism
and decreased levels of catechol-O-methyl-transferase
(COMT) in the forebrain compared to controls [5,12].
When examining the protein expression in the ‘nucleus
accumbens’ of DVD-deﬁcient rats, alterations in several pro-
teins in calcium binding and mitochondrial function were
observed [3]. Altered responses in the behaviour of DVD-deﬁ-
cient animals such as increased novelty-induced locomotion
can be inﬂuenced by the sub-cortical DA system, reﬂecting a
possible DA dysfunction [5].Vitamin D and GDNF
Vitamin D is a potent inducer of endogenous GDNF. The
most prominent feature of GDNF is its ability to support
the survival of dopaminergic neurons. GDNF is involved in
the development of the dopaminergic pathways and regulates
dopaminergic cell apoptosis in the substantia nigra in the
immediate postnatal period [13]. It has been shown that
DVD-deﬁcient neonatal rats have reduced expression of
GDNF in the cerebrum [13]. The development of the dopami-
nergic neurons within the ventral tegmental area (VTA) can be
inﬂuenced by altered GDNF, leading to an altered DA release
within the ‘nucleus accumbens’. It has been speculated that the
orderly development of the dopaminergic pathways may be al-
tered because of hypovitaminosis D-induced reductions in
GDNF [13].
Vitamin D and drugs
Vitamin D administration provides protection against the
DA- and serotonin-depleting effects of methamphetamine
in the brain of animals when neurotoxic doses of the drug
are repeatedly administered [14]. One study investigating
DVD deﬁciency in adult rats showed that female DVD-
deﬁcient rats travelled signiﬁcantly further than control rats
in a locomotion test after an acute dose of amphetamine
[11].
A single-point binding study made by the same group
showed that DVD-deﬁcient female rats had increased dopa-
mine transporter (DAT) binding in the caudate putamen
and nucleus accumbens compared to controls, indicating that
the increased amphetamine-induced locomotion in female
DVD-deﬁcient rats is caused by the increased striatal DAT
density and/or nucleus accumbens afﬁnity [11]. The study
demonstrates that DA release after amphetamine treatment
could be facilitated by increased DAT density or afﬁnity,
which would lead to the enhanced locomotor response
observed [11]. However, it is unknown if DA release is in-
creased in the brains of these animals in response to
amphetamine [11].
Vitamin D intake · status · adverse effects
The determinant of vitamin D status is the serum concentra-
tion of 25-hydroxyvitamin D (25(OH)D). Investigators agree
that optimal serum 25(OH)D should be approximately
50 nmol l1. Many studies point to a toxicity threshold for
vitamin D of 10,000–40,000 IU day1 and serum 25(OH)D lev-
els of 500–600 nmol l1 [15].
Adverse effects observed in vitamin D administration in-
clude weakness, anorexia, polyuria, heart arrhythmia, metal
taste in the mouth, diarrhoea and excessively high levels of cal-
cium in the blood, which might lead to damage to the heart,
blood vessels and kidneys, due to vascular and tissue calciﬁca-
tion [15].
Symptoms of toxicity are unlikely at doses below
10,000 IU day1, although some studies suggest that lower
doses might have adverse health effects over time, recommend-
ing that 25(OH)D serum levels above 125–150 nmol l1 should
be avoided [15].
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It could be speculated that vitamin D would be an effective
treatment approach for drug abuse and addiction, if we accept
that vitamin D would provide protection for the dopaminergic
system against DA-depleting effects of drugs (Fig. 1), as it was
shown for methamphetamine [14].
Evaluation of the hypothesis
First, studies using animals should be designed to evaluate this
hypothesis. A possibleway to conﬁrm this hypothesis is to evaluate
the effect of vitamin D on the acquisition of drug-
conditioned place preference (CPP) in mice or rats. Conditioned
stimuli induce uncontrollable craving for the drug, leading to re-
lapse in abstinent patients [16]. The CPP model is based on this
mechanism and has been widely used in the investigation of new
pharmacological treatments for drug dependence [17]. The CPP
apparatus provides two compartments with the same dimensions
that differ with regard to the wall pattern and the texture of the
ﬂoor. Therefore, there are visual and tactile differences between
them. The administration of the drug must be randomly paired
with any one compartment (unbiased method) [18].
The conditioning regime should be 8 days long, and vitamin
D should be given immediately at the end of each conditioning
session. The duration of the vitamin D treatment was based on
studies in which 8 days of vitamin D administration (1.0 lg/kg/
day) has been shown to up-regulate GDNF expression andFigure 1 A diagrammatic reprprotein levels in the brain [9,19,20]. The test for CPP should
be carried out 24 h after the last session, during which animals
have free access to both compartments and the time they spend
in each compartment is measured.
To conﬁrm this hypothesis, the results must show that ani-
mals treated with vitamin D spend signiﬁcantly less time in the
drug-paired compartment than the ones treated with placebo.
Therefore, this ﬁnding would represent a reduction in the con-
solidation of drug-induced CPP. Another possible way is to
evaluate the effect of vitamin D on a drug self-administration
study in which animals are treated with vitamin D after acqui-
sition of drug self-administration. To conﬁrm this hypothesis,
vitamin D treatment must decrease maintenance levels of drug
self-administration. If studies using animals show encouraging
results, appropriate clinical trials should be designed in order
to evaluate this hypothesis. A possible way to evaluate the ef-
fect of vitamin D in drug abuse and addiction in humans is to
conduct a placebo-controlled, double blind, randomised study
where drug-dependent patients are placed in two groups: ‘Vita-
min D’ and ‘Placebo’. The doses chosen for the study must be
below the toxicity threshold for vitamin D. Patients in the vita-
min D group should demonstrate reduction in drug use when
compared to controls, providing support for the utility of vita-
min D in the treatment of drug abuse and addiction.
Discussion
Vitamin D-treated animals showed signiﬁcant attenuated
methamphetamine-induced reductions in DA and metabolitesesentation of the hypothesis.
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protection for the dopaminergic system against the depleting
effects of methamphetamine [14].
Drugs of abuse increase DA action by increasingDA release,
inhibiting DA re-uptake or increasing post-synaptic sensitivity
to DA. These drugs act through different mechanisms and on
different locations in the brain reward system. It has been
shown that cocaine, amphetamine, marijuana, nicotine and opi-
ates stimulate neurons in ‘nucleus accumbens’, while alcohol,
opiates, benzodiazepines and barbiturates stimulate neurons
in the VTA; nevertheless, all of them share a ﬁnal action in
which they increase DA levels in the reward pathway [21].
The protective effects of vitamin D might be due to a mech-
anism of up-regulation of GDNF [14], as it was shown that
when GDNF is administered directly into the striatum before
methamphetamine treatment, complete protection against the
dopaminergic toxicity of methamphetamine, such as reduc-
tions in striatal DA release and content, could be observed
[22]. Vitamin D also increases glutathione levels and inhibits
inducible nitric oxide synthase (iNOS) production, which
could reduce methamphetamine toxicity to the DA system
by reducing methamphetamine free radicals’ production [14].
Conclusion
The evidences from literature concerning vitamin D and the
central nervous system support the plausibility of this hypoth-
esis, which can provide a new direction towards an effective
treatment approach for drug abuse and addiction. If vitamin
D treatment proves effective, many patients would beneﬁt from
it, as vitamin D is an accessible, safe and inexpensive treatment.
In conclusion, advances in drug-abuse research may contribute
towards new choices in drug-abuse treatment, as we have no
pharmacological treatments at our disposal at the present mo-
ment, although several issues need further investigation.Overview Box
First Question: What do we already know about the
subject?
Drug addiction is a serious public health problem
without effective treatment so far. All drugs of abuse in-
crease DA levels. Vitamin D may be involved in neurode-
velopment and may have a neuroprotective effect on
dopaminergic pathways in the adult brain.
Second Question: What does your proposed theory add to
the current knowledge available andwhat beneﬁts does it have?
Although many studies focus on new pharmacological
treatments for drug abuse and addiction, none has proven
successful. If vitamin D treatment proves to be effective, a
new way to treat patients could be established and a better
understanding of the role of vitamin D in dopaminergic
pathways would be set.
Third question: Among numerous available studies, what
special further study is proposed for testing the idea?
In order to evaluate whether vitamin D is an effective
treatment for drug abuse and addiction, studies (using
animals) such as CPP or drug self-administration should
be conducted. If encouraging results are shown, a pla-
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